Adapting and piloting a vaccine hesitancy questionnaire in rural Guatemala
•We adapted a Spanish language vaccine hesitancy tool to Guatemala with implementation science.•We piloted it with 150 parents, scoring it from 0 (not hesitant) to 10 (most hesitant).•45% (n = 67) parents scored 0, 41% (n = 61) scored 1–3, and 15% (n = 22) scored ≥ 4.•Most parents scoring > 0 wor...
Gespeichert in:
Veröffentlicht in: | Vaccine 2021-01, Vol.39 (2), p.180-184 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •We adapted a Spanish language vaccine hesitancy tool to Guatemala with implementation science.•We piloted it with 150 parents, scoring it from 0 (not hesitant) to 10 (most hesitant).•45% (n = 67) parents scored 0, 41% (n = 61) scored 1–3, and 15% (n = 22) scored ≥ 4.•Most parents scoring > 0 worried children get more vaccines than are good for them.•Children of parents scoring ≥ 4 had decreased odds of timely vaccination at age 19 months.
We sought to (i) adapt a Spanish-language vaccine hesitancy (VH) tool to rural Guatemala, (ii) pilot the tool with 150 parents of children ≤ 5 years, and (iii) measure if parent scores associated with child under-vaccination.
We used implementation science to develop the adapted Guatemalan Vaccine Attitudes (GuaVA) tool, piloting it with 150 parents of children ≤ 5 years, and performing descriptive and adjusted regression analyses.
Of 150 parents (response rate 99%), 55% (n = 83) of parents expressed a degree of VH. Children of parents with highly hesitant scores (n = 22) had 2.5 times the odds (OR 2.5; 95% CI: 1.2, 5.4) of being undervaccinated at 19 months, referent children of non-hesitant parents (n = 67).
Vaccine hesitancy may be more prevalent in rural Guatemala than suspected. Implementation science facilitated the adaptation of a VH tool to rural Guatemala and may assist investigators in other settings. |
---|---|
ISSN: | 0264-410X 1873-2518 |
DOI: | 10.1016/j.vaccine.2020.11.069 |